2000
[DOCID: f:h956enr.txt]
H.R.956
One Hundred Fourth Congress
of the
United States of America
AT THE SECOND SESSION
Begun and held at the City of Washington on Wednesday,
the third day of January, one thousand nine hundred and ninety-six
An Act
To establish legal standards and procedures for product liability
litigation, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE AND TABLE OF CONTENTS.
(a) Short Title.--This Act may be cited as the ``Common Sense
Product Liability Legal Reform Act of 1996''.
(b) Table of Contents.--The table of contents is as follows:
Sec. 1. Short title and table of contents.
Sec. 2. Findings and purposes.
TITLE I--PRODUCT LIABILITY REFORM
Sec. 101. Definitions.
Sec. 102. Applicability; preemption.
Sec. 103. Liability rules applicable to product sellers, renters, and
lessors.
Sec. 104. Defense based on claimant's use of intoxicating alcohol or
drugs.
Sec. 105. Misuse or alteration.
Sec. 106. Uniform time limitations on liability.
Sec. 107. Alternative dispute resolution procedures.
Sec. 108. Uniform standards for award of punitive damages.
Sec. 109. Liability for certain claims relating to death.
Sec. 110. Several liability for noneconomic loss.
Sec. 111. Workers' compensation subrogation.
TITLE II--BIOMATERIALS ACCESS ASSURANCE
Sec. 201. Short title.
Sec. 202. Findings.
Sec. 203. Definitions.
Sec. 204. General requirements; applicability; preemption.
Sec. 205. Liability of biomaterials suppliers.
Sec. 206. Procedures for dismissal of civil actions against biomaterials
suppliers.
TITLE III--LIMITATIONS ON APPLICABILITY; EFFECTIVE DATE
Sec. 301. Effect of court of appeals decisions.
Sec. 302. Federal cause of action precluded.
Sec. 303. Effective date.
SEC. 2. FINDINGS AND PURPOSES.
(a) Findings.--The Congress finds that--
(1) our Nation is overly litigious, the civil justice system is
overcrowded, sluggish, and excessively costly and the costs of
lawsuits, both direct and indirect, are inflicting serious and
unnecessary injury on the national economy;
(2) excessive, unpredictable, and often arbitrary damage awards
and unfair allocations of liability have a direct and undesirable
effect on interstate commerce by increasing the cost and decreasing
the availability of goods and services;
(3) the rules of law governing product liability actions,
damage awards, and allocations of liability have evolved
inconsistently within and among the States, resulting in a complex,
contradictory, and uncertain regime that is inequitable to both
plaintiffs and defendants and unduly burdens interstate commerce;
(4) as a result of excessive, unpredictable, and often
arbitrary damage awards and unfair allocations of liability,
consumers have been adversely affected through the withdrawal of
products, producers, services, and service providers from the
marketplace, and from excessive liability costs passed on to them
through higher prices;
(5) excessive, unpredictable, and often arbitrary damage awards
and unfair allocations of liability jeopardize the financial well-
being of many individuals as well as entire industries,
particularly the Nation's small businesses and adversely affects
government and taxpayers;
(6) the excessive costs of the civil justice system undermine
the ability of American companies to compete internationally, and
serve to decrease the number of jobs and the amount of productive
capital in the national economy;
(7) the unpredictability of damage awards is inequitable to
both plaintiffs and defendants and has added considerably to the
high cost of liability insurance, making it difficult for
producers, consumers, volunteers, and nonprofit organizations to
protect themselves from liability with any degree of confidence and
at a reasonable cost;
(8) because of the national scope of the problems created by
the defects in the civil justice system, it is not possible for the
States to enact laws that fully and effectively respond to those
problems;
(9) it is the constitutional role of the national government to
remove barriers to interstate commerce and to protect due process
rights; and
(10) there is a need to restore rationality, certainty, and
fairness to the civil justice system in order to protect against
excessive, arbitrary, and uncertain damage awards and to reduce the
volume, costs, and delay of litigation.
(b) Purposes.--Based upon the powers contained in Article I,
Section 8, Clause 3 and the Fourteenth Amendment of the United States
Constitution, the purposes of this Act are to promote the free flow of
goods and services and to lessen burdens on interstate commerce and to
uphold constitutionally protected due process rights by--
(1) establishing certain uniform legal principles of product
liability which provide a fair balance among the interests of
product users, manufacturers, and product sellers;
(2) placing reasonable limits on damages over and above the
actual damages suffered by a claimant;
(3) ensuring the fair allocation of liability in civil actions;
(4) reducing the unacceptable costs and delays of our civil
justice system caused by excessive litigation which harm both
plaintiffs and defendants; and
(5) establishing greater fairness, rationality, and
predictability in the civil justice system.
TITLE I--PRODUCT LIABILITY REFORM
SEC. 101. DEFINITIONS.
For purposes of this title--
(1) Actual malice.--The term ``actual malice'' means specific
intent to cause serious physical injury, illness, disease, death,
or damage to property.
(2) Claimant.--The term ``claimant'' means any person who
brings an action covered by this title and any person on whose
behalf such an action is brought. If such an action is brought
through or on behalf of an estate, the term includes the claimant's
decedent. If such an action is brought through or on behalf of a
minor or incompetent, the term includes the claimant's legal
guardian.
(3) Claimant's benefits.--The term ``claimant's benefits''
means the amount paid to an employee as workers' compensation
benefits.
(4) Clear and convincing evidence.--The term ``clear and
convincing evidence'' is that measure or degree of proof that will
produce in the mind of the trier of fact a firm belief or
conviction as to the truth of the allegations sought to be
established. The level of proof required to satisfy such standard
is more than that required under preponderance of the evidence, but
less than that required for proof beyond a reasonable doubt.
(5) Commercial loss.--The term ``commercial loss'' means any
loss or damage solely to a product itself, loss relating to a
dispute over its value, or consequential economic loss, the
recovery of which is governed by the Uniform Commercial Code or
analogous State commercial or contract law.
(6) Compensatory damages.--The term ``compensatory damages''
means damages awarded for economic and non-economic loss.
(7) Durable good.--The term ``durable good'' means any product,
or any component of any such product, which has a normal life
expectancy of 3 or more years, or is of a character subject to
allowance for depreciation under the Internal Revenue Code of 1986
and which is--
(A) used in a trade or business;
(B) held for the production of income; or
(C) sold or donated to
2000
a governmental or private entity for
the production of goods, training, demonstration, or any other
similar purpose.
(8) Economic loss.--The term ``economic loss'' means any
pecuniary loss resulting from harm (including the loss of earnings
or other benefits related to employment, medical expense loss,
replacement services loss, loss due to death, burial costs, and
loss of business or employment opportunities) to the extent
recovery for such loss is allowed under applicable State law.
(9) Harm.--The term ``harm'' means any physical injury,
illness, disease, or death or damage to property caused by a
product. The term does not include commercial loss.
(10) Insurer.--The term ``insurer'' means the employer of a
claimant if the employer is self-insured or if the employer is not
self-insured, the workers' compensation insurer of the employer.
(11) Manufacturer.--The term ``manufacturer'' means--
(A) any person who is engaged in a business to produce,
create, make, or construct any product (or component part of a
product) and who (i) designs or formulates the product (or
component part of the product), or (ii) has engaged another
person to design or formulate the product (or component part of
the product);
(B) a product seller, but only with respect to those
aspects of a product (or component part of a product) which are
created or affected when, before placing the product in the
stream of commerce, the product seller produces, creates, makes
or constructs and designs, or formulates, or has engaged
another person to design or formulate, an aspect of the product
(or component part of the product) made by another person; or
(C) any product seller not described in subparagraph (B)
which holds itself out as a manufacturer to the user of the
product.
(12) Noneconomic loss.--The term ``noneconomic loss'' means
subjective, nonmonetary loss resulting from harm, including pain,
suffering, inconvenience, mental suffering, emotional distress,
loss of society and companionship, loss of consortium, injury to
reputation, and humiliation.
(13) Person.--The term ``person'' means any individual,
corporation, company, association, firm, partnership, society,
joint stock company, or any other entity (including any
governmental entity).
(14) Product.--
(A) In general.--The term ``product'' means any object,
substance, mixture, or raw material in a gaseous, liquid, or
solid state which--
(i) is capable of delivery itself or as an assembled
whole, in a mixed or combined state, or as a component part
or ingredient;
(ii) is produced for introduction into trade or
commerce;
(iii) has intrinsic economic value; and
(iv) is intended for sale or lease to persons for
commercial or personal use.
(B) Exclusion.--The term does not include--
(i) tissue, organs, blood, and blood products used for
therapeutic or medical purposes, except to the extent that
such tissue, organs, blood, and blood products (or the
provision thereof) are subject, under applicable State law,
to a standard of liability other than negligence; or
(ii) electricity, water delivered by a utility, natural
gas, or steam except to the extent that electricity, water
delivered by a utility, natural gas, or steam, is subject,
under applicable State law, to a standard of liability
other than negligence.
(15) Product liability action.--The term ``product liability
action'' means a civil action brought on any theory for harm caused
by a product.
(16) Product seller.--
(A) In general.--The term ``product seller'' means a person
who in the course of a business conducted for that purpose--
(i) sells, distributes, rents, leases, prepares,
blends, packages, labels, or otherwise is involved in
placing a product in the stream of commerce; or
(ii) installs, repairs, refurbishes, reconditions, or
maintains the harm-causing aspect of the product.
(B) Exclusion.--The term ``product seller'' does not
include--
(i) a seller or lessor of real property;
(ii) a provider of professional services in any case in
which the sale or use of a product is incidental to the
transaction and the essence of the transaction is the
furnishing of judgment, skill, or services; or
(iii) any person who--
(I) acts in only a financial capacity with respect
to the sale of a product; or
(II) leases a product under a lease arrangement in
which the lessor does not initially select the leased
product and does not during the lease term ordinarily
control the daily operations and maintenance of the
product.
(17) Punitive damages.--The term ``punitive damages'' means
damages awarded against any person or entity to punish or deter
such person or entity, or others, from engaging in similar behavior
in the future.
(18) State.--The term ``State'' means any State of the United
States, the District of Columbia, Commonwealth of Puerto Rico, the
Northern Mariana Islands, the Virgin Islands, Guam, American Samoa,
and any other territory or possession of the United States or any
political subdivision of any of the foregoing.
SEC. 102. APPLICABILITY; PREEMPTION.
(a) Preemption.--
(1) In general.--This Act governs any product liability action
brought in any State or Federal court on any theory for harm caused
by a product.
(2) Actions excluded.--A civil action brought for commercial
loss shall be governed only by applicable commercial or contract
law.
(b) Relationship to State Law.--This title supersedes State law
only to the extent that State law applies to an issue covered by this
title. Any issue that is not governed by this title, including any
standard of liability applicable to a manufacturer, shall be governed
by otherwise applicable State or Federal law.
(c) Effect on Other Law.--Nothing in this Act shall be construed
to--
(1) waive or affect any defense of sovereign immunity asserted
by any State under any law;
(2) supersede or alter any Federal law;
(3) waive or affect any defense of sovereign immunity asserted
by the United States;
(4) affect the applicability of any provision of chapter 97 of
title 28, United States Code;
(5) preempt State choice-of-law rules with respect to claims
brought by a foreign nation or a citizen of a foreign nation;
(6) affect the right of any court to transfer venue or to apply
the law of a foreign nation or to dismiss a claim of a foreign
nation or of a citizen of a foreign nation on the ground of
inconvenient forum; or
(7) supersede or modify any statutory or common law, including
any law providing for an action to abate a nuisance, that
authorizes a person to institute an action for civil damages or
civil penalties, cleanup costs, injunctions, restitution, cost
recovery, punitive damages, or any other form of relief for
remediation of the environment (as defined in section 101(8) of the
Comprehensive Environmental Response, Compensation, and Liability
Act of 1980 (42 U.S.C. 9601(8)).
SEC. 103. LIABILITY RULES APPLICABLE TO PRODUCT SELLERS, RENTERS, AND
LESSORS.
(a) General Rule.--
(1) In general.--In any product liability action, a prod
2000
uct
seller other than a manufacturer shall be liable to a claimant only
if the claimant establishes--
(A) that--
(i) the product that allegedly caused the harm that is
the subject of the complaint was sold, rented, or leased by
the product seller;
(ii) the product seller failed to exercise reasonable
care with respect to the product; and
(iii) the failure to exercise reasonable care was a
proximate cause of harm to the claimant;
(B) that--
(i) the product seller made an express warranty
applicable to the product that allegedly caused the harm
that is the subject of the complaint, independent of any
express warranty made by a manufacturer as to the same
product;
(ii) the product failed to conform to the warranty; and
(iii) the failure of the product to conform to the
warranty caused harm to the claimant; or
(C) that--
(i) the product seller engaged in intentional
wrongdoing, as determined under applicable State law; and
(ii) such intentional wrongdoing was a proximate cause
of the harm that is the subject of the complaint.
(2) Reasonable opportunity for inspection.--For purposes of
paragraph (1)(A)(ii), a product seller shall not be considered to
have failed to exercise reasonable care with respect to a product
based upon an alleged failure to inspect the product--
(A) if the failure occurred because there was no reasonable
opportunity to inspect the product; or
(B) if the inspection, in the exercise of reasonable care,
would not have revealed the aspect of the product which
allegedly caused the claimant's harm.
(b) Special Rule.--
(1) In general.--A product seller shall be deemed to be liable
as a manufacturer of a product for harm caused by the product if--
(A) the manufacturer is not subject to service of process
under the laws of any State in which the action may be brought;
or
(B) the court determines that the claimant would be unable
to enforce a judgment against the manufacturer.
(2) Statute of limitations.--For purposes of this subsection
only, the statute of limitations applicable to claims asserting
liability of a product seller as a manufacturer shall be tolled
from the date of the filing of a complaint against the manufacturer
to the date that judgment is entered against the manufacturer.
(c) Rented or Leased Products.--
(1) Notwithstanding any other provision of law, any person
engaged in the business of renting or leasing a product (other than
a person excluded from the definition of product seller under
section 101(16)(B)) shall be subject to liability in a product
liability action under subsection (a), but any person engaged in
the business of renting or leasing a product shall not be liable to
a claimant for the tortious act of another solely by reason of
ownership of such product.
(2) For purposes of paragraph (1), and for determining the
applicability of this title to any person subject to paragraph (1),
the term ``product liability action'' means a civil action brought
on any theory for harm caused by a product or product use.
(d) Actions for Negligent Entrustment.--A civil action for
negligent entrustment shall not be subject to the provisions of this
section, but shall be subject to any applicable State law.
SEC. 104. DEFENSE BASED ON CLAIMANT'S USE OF INTOXICATING ALCOHOL OR
DRUGS.
(a) General Rule.--In any product liability action, it shall be a
complete defense to such action if--
(1) the claimant was intoxicated or was under the influence of
intoxicating alcohol or any drug when the accident or other event
which resulted in such claimant's harm occurred; and
(2) the claimant, as a result of the influence of the alcohol
or drug, was more than 50 percent responsible for such accident or
other event.
(b) Construction.--For purposes of subsection (a)--
(1) the determination of whether a person was intoxicated or
was under the influence of intoxicating alcohol or any drug shall
be made pursuant to applicable State law; and
(2) the term ``drug'' means any controlled substance as defined
in the Controlled Substances Act (21 U.S.C. 802(6)) that was not
legally prescribed for use by the claimant or that was taken by the
claimant other than in accordance with the terms of a lawfully
issued prescription.
SEC. 105. MISUSE OR ALTERATION.
(a) General Rule.--
(1) In general.--In a product liability action, the damages for
which a defendant is otherwise liable under Federal or State law
shall be reduced by the percentage of responsibility for the
claimant's harm attributable to misuse or alteration of a product
by any person if the defendant establishes that such percentage of
the claimant's harm was proximately caused by a use or alteration
of a product--
(A) in violation of, or contrary to, a defendant's express
warnings or instructions if the warnings or instructions are
adequate as determined pursuant to applicable State law; or
(B) involving a risk of harm which was known or should have
been known by the ordinary person who uses or consumes the
product with the knowledge common to the class of persons who
used or would be reasonably anticipated to use the product.
(2) Use intended by a manufacturer is not misuse or
alteration.--For the purposes of this Act, a use of a product that
is intended by the manufacturer of the product does not constitute
a misuse or alteration of the product.
(b) Workplace Injury.--Notwithstanding subsection (a), and except
as otherwise provided in section 111, the damages for which a defendant
is otherwise liable under State law shall not be reduced by the
percentage of responsibility for the claimant's harm attributable to
misuse or alteration of the product by the claimant's employer or any
coemployee who is immune from suit by the claimant pursuant to the
State law applicable to workplace injuries.
SEC. 106. UNIFORM TIME LIMITATIONS ON LIABILITY.
(a) Statute of Limitations.--
(1) In general.--Except as provided in paragraph (2) and
subsection (b), a product liability action may be filed not later
than 2 years after the date on which the claimant discovered or, in
the exercise of reasonable care, should have discovered--
(A) the harm that is the subject of the action; and
(B) the cause of the harm.
(2) Exception.--A person with a legal disability (as determined
under applicable law) may file a product liability action not later
than 2 years after the date on which the person ceases to have the
legal disability.
(b) Statute of Repose.--
(1) In general.--Subject to paragraphs (2) and (3), no product
liability action that is subject to this Act concerning a product,
that is a durable good, alleged to have caused harm (other than
toxic harm) may be filed after the 15-year period beginning at the
time of delivery of the product to the first purchaser or lessee.
(2) State law.--Notwithstanding paragraph (1), if pursuant to
an applicable State law, an action described in such paragraph is
required to be filed during a period that is shorter than the 15-
year period specified in such paragraph, the State law shall apply
with respect to such period.
(3) Exceptions.--
(A) A motor vehicle, vessel, aircraft, or train, that is
used primarily to transport passengers for hire, shall not be
subject to this subsection.
(B) Parag
2000
raph (1) does not bar a product liability action
against a defendant who made an express warranty in writing as
to the safety or life expectancy of the specific product
involved which was longer than 15 years, but it will apply at
the expiration of that warranty.
(C) Paragraph (1) does not affect the limitations period
established by the General Aviation Revitalization Act of 1994
(49 U.S.C. 40101 note).
(c) Transitional Provision Relating to Extension of Period for
Bringing Certain Actions.--If any provision of subsection (a) or (b)
shortens the period during which a product liability action could be
otherwise brought pursuant to another provision of law, the claimant
may, notwithstanding subsections (a) and (b), bring the product
liability action not later than 1 year after the date of enactment of
this Act.
SEC. 107. ALTERNATIVE DISPUTE RESOLUTION PROCEDURES.
(a) Service of Offer.--A claimant or a defendant in a product
liability action may, not later than 60 days after the service of--
(1) the initial complaint; or
(2) the applicable deadline for a responsive pleading;
whichever is later, serve upon an adverse party an offer to proceed
pursuant to any voluntary, nonbinding alternative dispute resolution
procedure established or recognized under the law of the State in which
the product liability action is brought or under the rules of the court
in which such action is maintained.
(b) Written Notice of Acceptance or Rejection.--Except as provided
in subsection (c), not later than 10 days after the service of an offer
to proceed under subsection (a), an offeree shall file a written notice
of acceptance or rejection of the offer.
(c) Extension.--The court may, upon motion by an offeree made prior
to the expiration of the 10-day period specified in subsection (b),
extend the period for filling a written notice under such subsection
for a period of not more than 60 days after the date of expiration of
the period specified in subsection (b). Discovery may be permitted
during such period.
SEC. 108. UNIFORM STANDARDS FOR AWARD OF PUNITIVE DAMAGES.
(a) General Rule.--Punitive damages may, to the extent permitted by
applicable State law, be awarded against a defendant if the claimant
establishes by clear and convincing evidence that conduct carried out
by the defendant with a conscious, flagrant indifference to the rights
or safety of others was the proximate cause of the harm that is the
subject of the action in any product liability action.
(b) Limitation on Amount.--
(1) In general.--The amount of punitive damages that may be
awarded in an action described in subsection (a) may not exceed the
greater of--
(A) 2 times the sum of the amount awarded to the claimant
for economic loss and noneconomic loss; or
(B) $250,000.
(2) Special rule.--Notwithstanding paragraph (1), in any action
described in subsection (a) against an individual whose net worth
does not exceed $500,000 or against an owner of an unincorporated
business, or any partnership, corporation, association, unit of
local government, or organization which has fewer that 25 full-time
employees, the punitive damages shall not exceed the lesser of--
(A) 2 times the sum of the amount awarded to the claimant
for economic loss and noneconomic loss; or
(B) $250,000.
For the purpose of determining the applicability of this paragraph
to a corporation, the number of employees of a subsidiary or
wholly-owned corporation shall include all employees of a parent or
sister corporation.
(3) Exception for insufficient award in cases of egregious
conduct.--
(A) Determination by court.--If the court makes a
determination, after considering each of the factors in
subparagraph (B), that the application of paragraph (1) would
result in an award of punitive damages that is insufficient to
punish the egregious conduct of the defendant against whom the
punitive damages are to be awarded or to deter such conduct in
the future, the court shall determine the additional amount of
punitive damages (referred to in this paragraph as the
``additional amount'') in excess of the amount determined in
accordance with paragraph (1) to be awarded against the
defendant in a separate proceeding in accordance with this
paragraph.
(B) Factors for consideration.--In any proceeding under
paragraph (A), the court shall consider--
(i) the extent to which the defendant acted with actual
malice;
(ii) the likelihood that serious harm would arise from
the conduct of the defendant;
(iii) the degree of the awareness of the defendant of
that likelihood;
(iv) the profitability of the misconduct to the
defendant;
(v) the duration of the misconduct and any concurrent
or subsequent concealment of the conduct by the defendant;
(vi) the attitude and conduct of the defendant upon the
discovery of the misconduct and whether the misconduct has
terminated;
(vii) the financial condition of the defendant; and
(viii) the cumulative deterrent effect of other losses,
damages, and punishment suffered by the defendant as a
result of the misconduct, reducing the amount of punitive
damages on the basis of the economic impact and severity of
all measures to which the defendant has been or may be
subjected, including--
(I) compensatory and punitive damage awards to
similarly situated claimants;
(II) the adverse economic effect of stigma or loss
of reputation;
(III) civil fines and criminal and administrative
penalties; and
(IV) stop sale, cease and desist, and other
remedial or enforcement orders.
(C) Requirements for awarding additional amount.--If the
court awards an additional amount pursuant to this subsection,
the court shall state its reasons for setting the amount of the
additional amount in findings of fact and conclusions of law.
(D) Preemption.--This section does not create a cause of
action for punitive damages and does not preempt or supersede
any State or Federal law to the extent that such law would
further limit the award of punitive damages. Nothing in this
subsection shall modify or reduce the ability of courts to
order remittiturs.
(4) Application by court.--This subsection shall be applied by
the court and application of this subsection shall not be disclosed
to the jury. Nothing in this subsection shall authorize the court
to enter an award of punitive damages in excess of the jury's
initial award of punitive damages.
(c) Bifurcation at Request of Any Party.--
(1) In general.--At the request of any party the trier of fact
in any action that is subject to this section shall consider in a
separate proceeding, held subsequent to the determination of the
amount of compensatory damages, whether punitive damages are to be
awarded for the harm that is the subject of the action and the
amount of the award.
(2) Inadmissibility of evidence relative only to a claim of
punitive damages in a proceeding concerning compensatory damages.--
If any party requests a separate proceeding under paragraph (1), in
a proceeding to determine whether the claimant may be awarded
compensatory damages, any evidence, argument, or contention that is
relevant only to the claim of punitive damages, as determined by
applicable State law, shall
2000
be inadmissible.
SEC. 109. LIABILITY FOR CERTAIN CLAIMS RELATING TO DEATH.
In any civil action in which the alleged harm to the claimant is
death and, as of the effective date of this Act, the applicable State
law provides, or has been construed to provide, for damages only
punitive in nature, a defendant may be liable for any such damages
without regard to section 108, but only during such time as the State
law so provides. This section shall cease to be effective September 1,
1996.
SEC. 110. SEVERAL LIABILITY FOR NONECONOMIC LOSS.
(a) General Rule.--In a product liability action, the liability of
each defendant for noneconomic loss shall be several only and shall not
be joint.
(b) Amount of Liability.--
(1) In general.--Each defendant shall be liable only for the
amount of noneconomic loss allocated to the defendant in direct
proportion to the percentage of responsibility of the defendant
(determined in accordance with paragraph (2)) for the harm to the
claimant with respect to which the defendant is liable. The court
shall render a separate judgment against each defendant in an
amount determined pursuant to the preceding sentence.
(2) Percentage of responsibility.--For purposes of determining
the amount of noneconomic loss allocated to a defendant under this
section, the trier of fact shall determine the percentage of
responsibility of each person responsible for the claimant's harm,
whether or not such person is a party to the action.
SEC. 111. WORKERS' COMPENSATION SUBROGATION.
(a) General Rule.--
(1) Right of subrogation.--
(A) In general.--An insurer shall have a right of
subrogation against a manufacturer or product seller to recover
any claimant's benefits relating to harm that is the subject of
a product liability action that is subject to this Act.
(B) Written notification.--To assert a right of subrogation
under subparagraph (A), the insurer shall provide written
notice to the court in which the product liability action is
brought.
(C) Insurer not required to be a party.--An insurer shall
not be required to be a necessary and proper party in a product
liability action covered under subparagraph (A).
(2) Settlements and other legal proceedings.--
(A) In general.--In any proceeding relating to harm or
settlement with the manufacturer or product seller by a
claimant who files a product liability action that is subject
to this Act, an insurer may participate to assert a right of
subrogation for claimant's benefits with respect to any payment
made by the manufacturer or product seller by reason of such
harm, without regard to whether the payment is made--
(i) as part of a settlement;
(ii) in satisfaction of judgment;
(iii) as consideration for a covenant not to sue; or
(iv) in another manner.
(B) Written notification.--Except as provided in
subparagraph (C), an employee shall not make any settlement
with or accept any payment from the manufacturer or product
seller without written notification to the insurer.
(C) Exemption.--Subparagraph (B) shall not apply in any
case in which the insurer has been compensated for the full
amount of the claimant's benefits.
(3) Harm resulting from action of employer or coemployee.--
(A) In general.--If, with respect to a product liability
action that is subject to this Act, the manufacturer or product
seller attempts to persuade the trier of fact that the harm to
the claimant was caused by the fault of the employer of the
claimant or any coemployee of the claimant, the issue of that
fault shall be submitted to the trier of fact, but only after
the manufacturer or product seller has provided timely written
notice to the insurer.
(B) Rights of insurer.--
(i) In general.--Notwithstanding any other provision of
law, with respect to an issue of fault submitted to a trier
of fact pursuant to subparagraph (A), an insurer shall, in
the same manner as any party in the action (even if the
insurer is not a named party in the action), have the right
to--
(I) appear;
(II) be represented;
(III) introduce evidence;
(IV) cross-examine adverse witnesses; and
(V) present arguments to the trier of fact.
(ii) Last issue.--The issue of harm resulting from an
action of an employer or coemployee shall be the last issue
that is submitted to the trier of fact.
(C) Reduction of damages.--If the trier of fact finds by
clear and convincing evidence that the harm to the claimant
that is the subject of the product liability action was caused
by the fault of the employer or a coemployee of the claimant--
(i) the court shall reduce by the amount of the
claimant's benefits--
(I) the damages awarded against the manufacturer or
product seller; and
(II) any corresponding insurer's subrogation lien;
and
(ii) the manufacturer or product seller shall have no
further right by way of contribution or otherwise against
the employer.
(D) Certain rights of subrogation not affected.--
Notwithstanding a finding by the trier of fact described in
subparagraph (C), the insurer shall not lose any right of
subrogation related to any--
(i) intentional tort committed against the claimant by
a coemployee; or
(ii) act committed by a coemployee outside the scope of
normal work practices.
(b) Attorney's Fees.--If, in a product liability action that is
subject to this section, the court finds that harm to a claimant was
not caused by the fault of the employer or a coemployee of the
claimant, the manufacturer or product seller shall reimburse the
insurer for reasonable attorney's fees and court costs incurred by the
insurer in the action, as determined by the court.
TITLE II--BIOMATERIALS ACCESS ASSURANCE
SEC. 201. SHORT TITLE.
This title may be cited as the ``Biomaterials Access Assurance Act
of 1996''.
SEC. 202. FINDINGS.
Congress finds that--
(1) each year millions of citizens of the United States depend
on the availability of lifesaving or life enhancing medical
devices, many of which are permanently implantable within the human
body;
(2) a continued supply of raw materials and component parts is
necessary for the invention, development, improvement, and
maintenance of the supply of the devices;
(3) most of the medical devices are made with raw materials and
component parts that--
(A) are not designed or manufactured specifically for use
in medical devices; and
(B) come in contact with internal human tissue;
(4) the raw materials and component parts also are used in a
variety of nonmedical products;
(5) because small quantities of the raw materials and component
parts are used for medical devices, sales of raw materials and
component parts for medical devices constitute an extremely small
portion of the overall market for the raw materials and medical
devices;
(6) under the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
301 et seq.), manufacturers of medical devices are required to
demonstrate that the medical devices are safe and effective,
including demonstrating that the products are properly designed and
have adequate warnings or instructions;
(
2000
7) notwithstanding the fact that raw materials and component
parts suppliers do not design, produce, or test a final medical
device, the suppliers have been the subject of actions alleging
inadequate--
(A) design and testing of medical devices manufactured with
materials or parts supplied by the suppliers; or
(B) warnings related to the use of such medical devices;
(8) even though suppliers of raw materials and component parts
have very rarely been held liable in such actions, such suppliers
have ceased supplying certain raw materials and component parts for
use in medical devices because the costs associated with litigation
in order to ensure a favorable judgment for the suppliers far
exceeds the total potential sales revenues from sales by such
suppliers to the medical device industry;
(9) unless alternate sources of supply can be found, the
unavailability of raw materials and component parts for medical
devices will lead to unavailability of lifesaving and life-
enhancing medical devices;
(10) because other suppliers of the raw materials and component
parts in foreign nations are refusing to sell raw materials or
component parts for use in manufacturing certain medical devices in
the United States, the prospects for development of new sources of
supply for the full range of threatened raw materials and component
parts for medical devices are remote;
(11) it is unlikely that the small market for such raw
materials and component parts in the United States could support
the large investment needed to develop new suppliers of such raw
materials and component parts;
(12) attempts to develop such new suppliers would raise the
cost of medical devices;
(13) courts that have considered the duties of the suppliers of
the raw materials and component parts have generally found that the
suppliers do not have a duty--
(A) to evaluate the safety and efficacy of the use of a raw
material or component part in a medical device; and
(B) to warn consumers concerning the safety and
effectiveness of a medical device;
(14) attempts to impose the duties referred to in subparagraphs
(A) and (B) of paragraph (13) on suppliers of the raw materials and
component parts would cause more harm than good by driving the
suppliers to cease supplying manufacturers of medical devices; and
(15) in order to safeguard the availability of a wide variety
of lifesaving and life-enhancing medical devices, immediate action
is needed--
(A) to clarify the permissible bases of liability for
suppliers of raw materials and component parts for medical
devices; and
(B) to provide expeditious procedures to dispose of
unwarranted suits against the suppliers in such manner as to
minimize litigation costs.
SEC. 203. DEFINITIONS.
As used in this title:
(1) Biomaterials supplier.--
(A) In general.--The term ``biomaterials supplier'' means
an entity that directly or indirectly supplies a component part
or raw material for use in the manufacture of an implant.
(B) Persons included.--Such term includes any person who--
(i) has submitted master files to the Secretary for
purposes of premarket approval of a medical device; or
(ii) licenses a biomaterials supplier to produce
component parts or raw materials.
(2) Claimant.--
(A) In general.--The term ``claimant'' means any person who
brings a civil action, or on whose behalf a civil action is
brought, arising from harm allegedly caused directly or
indirectly by an implant, including a person other than the
individual into whose body, or in contact with whose blood or
tissue, the implant is placed, who claims to have suffered harm
as a result of the implant.
(B) Action brought on behalf of an estate.--With respect to
an action brought on behalf of or through the estate of an
individual into whose body, or in contact with whose blood or
tissue the implant is placed, such term includes the decedent
that is the subject of the action.
(C) Action brought on behalf of a minor or incompetent.--
With respect to an action brought on behalf of or through a
minor or incompetent, such term includes the parent or guardian
of the minor or incompetent.
(D) Exclusions.--Such term does not include--
(i) a provider of professional health care services, in
any case in which--
(I) the sale or use of an implant is incidental to
the transaction; and
(II) the essence of the transaction is the
furnishing of judgment, skill, or services; or
(ii) a person acting in the capacity of a manufacturer,
seller, or biomaterials supplier.
(3) Component part.--
(A) In general.--The term ``component part'' means a
manufactured piece of an implant.
(B) Certain components.--Such term includes a manufactured
piece of an implant that--
(i) has significant non-implant applications; and
(ii) alone, has no implant value or purpose, but when
combined with other component parts and materials,
constitutes an implant.
(4) Harm.--
(A) In general.--The term ``harm'' means--
(i) any injury to or damage suffered by an individual;
(ii) any illness, disease, or death of that individual
resulting from that injury or damage; and
(iii) any loss to that individual or any other
individual resulting from that injury or damage.
(B) Exclusion.--The term does not include any commercial
loss or loss of or damage to an implant.
(5) Implant.--The term ``implant'' means--
(A) a medical device that is intended by the manufacturer
of the device--
(i) to be placed into a surgically or naturally formed
or existing cavity of the body for a period of at least 30
days; or
(ii) to remain in contact with bodily fluids or
internal human tissue through a surgically produced opening
for a period of less than 30 days; and
(B) suture materials used in implant procedures.
(6) Manufacturer.--The term ``manufacturer'' means any person
who, with respect to an implant--
(A) is engaged in the manufacture, preparation,
propagation, compounding, or processing (as defined in section
510(a)(1)) of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 360(a)(1)) of the implant; and
(B) is required--
(i) to register with the Secretary pursuant to section
510 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
360) and the regulations issued under such section; and
(ii) to include the implant on a list of devices filed
with the Secretary pursuant to section 510(j) of such Act
(21 U.S.C. 360(j)) and the regulations issued under such
section.
(7) Medical device.--The term ``medical device'' means a
device, as defined in section 201(h) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 321(h)) and includes any device component
of any combination product as that term is used in section 503(g)
of such Act (21 U.S.C. 353(g)).
(8) Raw material.--The term ``raw material'' means a substance
or product that--
(A) has a generic use; and
(B) may be used in an application other than an implant.
(9) Secretary.--The term ``Secretary'' m
2000
eans the Secretary of
Health and Human Services.
(10) Seller.--
(A) In general.--The term ``seller'' means a person who, in
the course of a business conducted for that purpose, sells,
distributes, leases, packages, labels, or otherwise places an
implant in the stream of commerce.
(B) Exclusions.--The term does not include--
(i) a seller or lessor of real property;
(ii) a provider of professional services, in any case
in which the sale or use of an implant is incidental to the
transaction and the essence of the transaction is the
furnishing of judgment, skill, or services; or
(iii) any person who acts in only a financial capacity
with respect to the sale of an implant.
SEC. 204. GENERAL REQUIREMENTS; APPLICABILITY; PREEMPTION.
(a) General Requirements.--
(1) In general.--In any civil action covered by this title, a
biomaterials supplier may raise any defense set forth in section
205.
(2) Procedures.--Notwithstanding any other provision of law,
the Federal or State court in which a civil action covered by this
title is pending shall, in connection with a motion for dismissal
or judgment based on a defense described in paragraph (1), use the
procedures set forth in section 206.
(b) Applicability.--
(1) In general.--Except as provided in paragraph (2),
notwithstanding any other provision of law, this title applies to
any civil action brought by a claimant, whether in a Federal or
State court, against a manufacturer, seller, or biomaterials
supplier, on the basis of any legal theory, for harm allegedly
caused by an implant.
(2) Exclusion.--A civil action brought by a purchaser of a
medical device for use in providing professional services against a
manufacturer, seller, or biomaterials supplier for loss or damage
to an implant or for commercial loss to the purchaser--
(A) shall not be considered an action that is subject to
this title; and
(B) shall be governed by applicable commercial or contract
law.
(c) Scope of Preemption.--
(1) In general.--This title supersedes any State law regarding
recovery for harm caused by an implant and any rule of procedure
applicable to a civil action to recover damages for such harm only
to the extent that this title establishes a rule of law applicable
to the recovery of such damages.
(2) Applicability of other laws.--Any issue that arises under
this title and that is not governed by a rule of law applicable to
the recovery of damages described in paragraph (1) shall be
governed by applicable Federal or State law.
(d) Statutory Construction.--Nothing in this title may be
construed--
(1) to affect any defense available to a defendant under any
other provisions of Federal or State law in an action alleging harm
caused by an implant; or
(2) to create a cause of action or Federal court jurisdiction
pursuant to section 1331 or 1337 of title 28, United States Code,
that otherwise would not exist under applicable Federal or State
law.
SEC. 205. LIABILITY OF BIOMATERIALS SUPPLIERS.
(a) In General.--
(1) Exclusion from liability.--Except as provided in paragraph
(2), a biomaterials supplier shall not be liable for harm to a
claimant caused by an implant.
(2) Liability.--A biomaterials supplier that--
(A) is a manufacturer may be liable for harm to a claimant
described in subsection (b);
(B) is a seller may be liable for harm to a claimant
described in subsection (c); and
(C) furnishes raw materials or component parts that fail to
meet applicable contractual requirements or specifications may
be liable for a harm to a claimant described in subsection (d).
(b) Liability as Manufacturer.--
(1) In general.--A biomaterials supplier may, to the extent
required and permitted by any other applicable law, be liable for
harm to a claimant caused by an implant if the biomaterials
supplier is the manufacturer of the implant.
(2) Grounds for liability.--The biomaterials supplier may be
considered the manufacturer of the implant that allegedly caused
harm to a claimant only if the biomaterials supplier--
(A)(i) has registered with the Secretary pursuant to
section 510 of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 360) and the regulations issued under such section; and
(ii) included the implant on a list of devices filed with
the Secretary pursuant to section 510(j) of such Act (21 U.S.C.
360(j)) and the regulations issued under such section;
(B) is the subject of a declaration issued by the Secretary
pursuant to paragraph (3) that states that the supplier, with
respect to the implant that allegedly caused harm to the
claimant, was required to--
(i) register with the Secretary under section 510 of
such Act (21 U.S.C. 360), and the regulations issued under
such section, but failed to do so; or
(ii) include the implant on a list of devices filed
with the Secretary pursuant to section 510(j) of such Act
(21 U.S.C. 360(j)) and the regulations issued under such
section, but failed to do so; or
(C) is related by common ownership or control to a person
meeting all the requirements described in subparagraph (A) or
(B), if the court deciding a motion to dismiss in accordance
with section 206(c)(3)(B)(i) finds, on the basis of affidavits
submitted in accordance with section 206, that it is necessary
to impose liability on the biomaterials supplier as a
manufacturer because the related manufacturer meeting the
requirements of subparagraph (A) or (B) lacks sufficient
financial resources to satisfy any judgment that the court
feels it is likely to enter should the claimant prevail.
(3) Administrative procedures.--
(A) In general.--The Secretary may issue a declaration
described in paragraph (2)(B) on the motion of the Secretary or
on petition by any person, after providing--
(i) notice to the affected persons; and
(ii) an opportunity for an informal hearing.
(B) Docketing and final decision.--Immediately upon receipt
of a petition filed pursuant to this paragraph, the Secretary
shall docket the petition. Not later than 180 days after the
petition is filed, the Secretary shall issue a final decision
on the petition.
(C) Applicability of statute of limitations.--Any
applicable statute of limitations shall toll during the period
during which a claimant has filed a petition with the Secretary
under this paragraph.
(c) Liability as Seller.--A biomaterials supplier may, to the
extent required and permitted by any other applicable law, be liable as
a seller for harm to a claimant caused by an implant if--
(1) the biomaterials supplier--
(A) held title to the implant that allegedly caused harm to
the claimant as a result of purchasing the implant after--
(i) the manufacture of the implant; and
(ii) the entrance of the implant in the stream of
commerce; and
(B) subsequently resold the implant; or
(2) the biomaterials supplier is related by common ownership or
control to a person meeting all the requirements described in
paragraph (1), if a court deciding a motion to dismiss in
accordance with section 206(c)(3)(B)(ii) finds, on the basis of
affidavits submitted in accordance with section 206, that it is
necessary to impose liabi
2000
lity on the biomaterials supplier as a
seller because the related seller meeting the requirements of
paragraph (1) lacks sufficient financial resources to satisfy any
judgment that the court feels it is likely to enter should the
claimant prevail.
(d) Liability for Violating Contractual Requirements or
Specifications.--A biomaterials supplier may, to the extent required
and permitted by any other applicable law, be liable for harm to a
claimant caused by an implant, if the claimant in an action shows, by a
preponderance of the evidence, that--
(1) the raw materials or component parts delivered by the
biomaterials supplier either--
(A) did not constitute the product described in the
contract between the biomaterials supplier and the person who
contracted for delivery of the product; or
(B) failed to meet any specifications that were--
(i) provided to the biomaterials supplier and not
expressly repudiated by the biomaterials supplier prior to
acceptance of delivery of the raw materials or component
parts;
(ii)(I) published by the biomaterials supplier;
(II) provided to the manufacturer by the biomaterials
supplier; or
(III) contained in a master file that was submitted by
the biomaterials supplier to the Secretary and that is
currently maintained by the biomaterials supplier for
purposes of premarket approval of medical devices; or
(iii) included in the submissions for purposes of
premarket approval or review by the Secretary under section
510, 513, 515, or 520 of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 360, 360c, 360e, or 360j), and
received clearance from the Secretary if such
specifications were provided by the manufacturer to the
biomaterials supplier and were not expressly repudiated by
the biomaterials supplier prior to the acceptance by the
manufacturer of delivery of the raw materials or component
parts; and
(2) such conduct was an actual and proximate cause of the harm
to the claimant.
SEC. 206. PROCEDURES FOR DISMISSAL OF CIVIL ACTIONS AGAINST
BIOMATERIALS SUPPLIERS.
(a) Motion To Dismiss.--In any action that is subject to this
title, a biomaterials supplier who is a defendant in such action may,
at any time during which a motion to dismiss may be filed under an
applicable law, move to dismiss the action against it on the grounds
that--
(1) the defendant is a biomaterials supplier; and
(2)(A) the defendant should not, for the purposes of--
(i) section 205(b), be considered to be a manufacturer of
the implant that is subject to such section; or
(ii) section 205(c), be considered to be a seller of the
implant that allegedly caused harm to the claimant; or
(B)(i) the claimant has failed to establish, pursuant to
section 205(d), that the supplier furnished raw materials or
component parts in violation of contractual requirements or
specifications; or
(ii) the claimant has failed to comply with the procedural
requirements of subsection (b).
(b) Manufacturer of Implant Shall Be Named a Party.--The claimant
shall be required to name the manufacturer of the implant as a party to
the action, unless--
(1) the manufacturer is subject to service of process solely in
a jurisdiction in which the biomaterials supplier is not domiciled
or subject to a service of process; or
(2) an action against the manufacturer is barred by applicable
law.
(c) Proceeding on Motion To Dismiss.--The following rules shall
apply to any proceeding on a motion to dismiss filed under this
section:
(1) Affidavits relating to listing and declarations.--
(A) In general.--The defendant in the action may submit an
affidavit demonstrating that defendant has not included the
implant on a list, if any, filed with the Secretary pursuant to
section 510(j) of the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 360(j)).
(B) Response to motion to dismiss.--In response to the
motion to dismiss, the claimant may submit an affidavit
demonstrating that--
(i) the Secretary has, with respect to the defendant
and the implant that allegedly caused harm to the claimant,
issued a declaration pursuant to section 205(b)(2)(B); or
(ii) the defendant who filed the motion to dismiss is a
seller of the implant who is liable under section 205(c).
(2) Effect of motion to dismiss on discovery.--
(A) In general.--If a defendant files a motion to dismiss
under paragraph (1) or (2) of subsection (a), no discovery
shall be permitted in connection to the action that is the
subject of the motion, other than discovery necessary to
determine a motion to dismiss for lack of jurisdiction, until
such time as the court rules on the motion to dismiss in
accordance with the affidavits submitted by the parties in
accordance with this section.
(B) Discovery.--If a defendant files a motion to dismiss
under subsection (a)(2)(B)(i) on the grounds that the
biomaterials supplier did not furnish raw materials or
component parts in violation of contractual requirements or
specifications, the court may permit discovery, as ordered by
the court. The discovery conducted pursuant to this
subparagraph shall be limited to issues that are directly
relevant to--
(i) the pending motion to dismiss; or
(ii) the jurisdiction of the court.
(3) Affidavits relating status of defendant.--
(A) In general.--Except as provided in clauses (i) and (ii)
of subparagraph (B), the court shall consider a defendant to be
a biomaterials supplier who is not subject to an action for
harm to a claimant caused by an implant, other than an action
relating to liability for a violation of contractual
requirements or specifications described in subsection (d).
(B) Responses to motion to dismiss.--The court shall grant
a motion to dismiss any action that asserts liability of the
defendant under subsection (b) or (c) of section 205 on the
grounds that the defendant is not a manufacturer subject to
such section 205(b) or seller subject to section 205(c), unless
the claimant submits a valid affidavit that demonstrates that--
(i) with respect to a motion to dismiss contending the
defendant is not a manufacturer, the defendant meets the
applicable requirements for liability as a manufacturer
under section 205(b); or
(ii) with respect to a motion to dismiss contending
that the defendant is not a seller, the defendant meets the
applicable requirements for liability as a seller under
section 205(c).
(4) Basis of ruling on motion to dismiss.--
(A) In general.--The court shall rule on a motion to
dismiss filed under subsection (a) solely on the basis of the
pleadings of the parties made pursuant to this section and any
affidavits submitted by the parties pursuant to this section.
(B) Motion for summary judgment.--Notwithstanding any other
provision of law, if the court determines that the pleadings
and affidavits made by parties pursuant to this section raise
genuine issues as concerning material facts with respect to a
motion concerning contractual requirements and specifications,
the court may deem the motion to dismiss to be a motion for
10c2
summary judgment made pursuant to subsection (d).
(d) Summary Judgment.--
(1) In general.--
(A) Basis for entry of judgment.--A biomaterials supplier
shall be entitled to entry of judgment without trial if the
court finds there is no genuine issue as concerning any
material fact for each applicable element set forth in
paragraphs (1) and (2) of section 205(d).
(B) Issues of material fact.--With respect to a finding
made under subparagraph (A), the court shall consider a genuine
issue of material fact to exist only if the evidence submitted
by claimant would be sufficient to allow a reasonable jury to
reach a verdict for the claimant if the jury found the evidence
to be credible.
(2) Discovery made prior to a ruling on a motion for summary
judgment.--If, under applicable rules, the court permits discovery
prior to a ruling on a motion for summary judgment made pursuant to
this subsection, such discovery shall be limited solely to
establishing whether a genuine issue of material fact exists as to
the applicable elements set forth in paragraphs (1) and (2) of
section 205(d).
(3) Discovery with respect to a biomaterials supplier.--A
biomaterials supplier shall be subject to discovery in connection
with a motion seeking dismissal or summary judgment on the basis of
the inapplicability of section 205(d) or the failure to establish
the applicable elements of section 205(d) solely to the extent
permitted by the applicable Federal or State rules for discovery
against nonparties.
(e) Stay Pending Petition for Declaration.--If a claimant has filed
a petition for a declaration pursuant to section 205(b)(3)(A) with
respect to a defendant, and the Secretary has not issued a final
decision on the petition, the court shall stay all proceedings with
respect to that defendant until such time as the Secretary has issued a
final decision on the petition.
(f) Manufacturer Conduct of Proceeding.--The manufacturer of an
implant that is the subject of an action covered under this title shall
be permitted to file and conduct a proceeding on any motion for summary
judgment or dismissal filed by a biomaterials supplier who is a
defendant under this section if the manufacturer and any other
defendant in such action enter into a valid and applicable contractual
agreement under which the manufacturer agrees to bear the cost of such
proceeding or to conduct such proceeding.
(g) Attorney Fees.--The court shall require the claimant to
compensate the biomaterials supplier (or a manufacturer appearing in
lieu of a supplier pursuant to subsection (f)) for attorney fees and
costs, if--
(1) the claimant named or joined the biomaterials supplier; and
(2) the court found the claim against the biomaterials supplier
to be without merit and frivolous.
TITLE III--LIMITATIONS ON APPLICABILITY; EFFECTIVE DATE
SEC. 301. EFFECT OF COURT OF APPEALS DECISIONS.
A decision by a Federal circuit court of appeals interpreting a
provision of this Act (except to the extent that the decision is
overruled or otherwise modified by the Supreme Court) shall be
considered a controlling precedent with respect to any subsequent
decision made concerning the interpretation of such provision by any
Federal or State court within the geographical boundaries of the area
under the jurisdiction of the circuit court of appeals.
SEC. 302. FEDERAL CAUSE OF ACTION PRECLUDED.
The district courts of the United States shall not have
jurisdiction pursuant to this Act based on section 1331 or 1337 of
title 28, United States Code.
SEC. 303. EFFECTIVE DATE.
This Act shall apply with respect to any action commenced on or
after the date of the enactment of this Act without regard to whether
the harm that is the subject of the action or the conduct that caused
the harm occurred before such date of enactment.
Speaker of the House of Representatives.
Vice President of the United States and
President of the Senate.
0